These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Comparison of Diagnostic Performances Between Cerebrospinal Fluid Biomarkers and Amyloid PET in a Clinical Setting. Jung NY; Kim ES; Kim HS; Jeon S; Lee MJ; Pak K; Lee JH; Lee YM; Lee K; Shin JH; Ko JK; Lee JM; Yoon JA; Hwang C; Choi KU; Lee EC; Seong JK; Huh GY; Kim DS; Kim EJ J Alzheimers Dis; 2020; 74(2):473-490. PubMed ID: 32039853 [TBL] [Abstract][Full Text] [Related]
11. Association of amyloid-β CSF/PET discordance and tau load 5 years later. Reimand J; Collij L; Scheltens P; Bouwman F; Ossenkoppele R; Neurology; 2020 Nov; 95(19):e2648-e2657. PubMed ID: 32913020 [TBL] [Abstract][Full Text] [Related]
13. Florbetapir positron emission tomography and cerebrospinal fluid biomarkers. Hake A; Trzepacz PT; Wang S; Yu P; Case M; Hochstetler H; Witte MM; Degenhardt EK; Dean RA; Alzheimers Dement; 2015 Aug; 11(8):986-93. PubMed ID: 25916563 [TBL] [Abstract][Full Text] [Related]
14. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Fleisher AS; Chen K; Liu X; Roontiva A; Thiyyagura P; Ayutyanont N; Joshi AD; Clark CM; Mintun MA; Pontecorvo MJ; Doraiswamy PM; Johnson KA; Skovronsky DM; Reiman EM Arch Neurol; 2011 Nov; 68(11):1404-11. PubMed ID: 21747008 [TBL] [Abstract][Full Text] [Related]
15. Application of Haralick texture features in brain [ Campbell DL; Kang H; Shokouhi S Clin Interv Aging; 2017; 12():2077-2086. PubMed ID: 29263656 [TBL] [Abstract][Full Text] [Related]
16. Improved longitudinal [(18)F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction. Brendel M; Högenauer M; Delker A; Sauerbeck J; Bartenstein P; Seibyl J; Rominger A; Neuroimage; 2015 Mar; 108():450-9. PubMed ID: 25482269 [TBL] [Abstract][Full Text] [Related]
17. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Doraiswamy PM; Sperling RA; Coleman RE; Johnson KA; Reiman EM; Davis MD; Grundman M; Sabbagh MN; Sadowsky CH; Fleisher AS; Carpenter A; Clark CM; Joshi AD; Mintun MA; Skovronsky DM; Pontecorvo MJ; Neurology; 2012 Oct; 79(16):1636-44. PubMed ID: 22786606 [TBL] [Abstract][Full Text] [Related]
18. Beta-amyloid deposition and cognitive function in patients with major depressive disorder with different subtypes of mild cognitive impairment: (18)F-florbetapir (AV-45/Amyvid) PET study. Wu KY; Liu CY; Chen CS; Chen CH; Hsiao IT; Hsieh CJ; Lee CP; Yen TC; Lin KJ Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1067-76. PubMed ID: 26739329 [TBL] [Abstract][Full Text] [Related]
19. Optimal Reference Region to Measure Longitudinal Amyloid-β Change with Bullich S; Villemagne VL; Catafau AM; Jovalekic A; Koglin N; Rowe CC; De Santi S J Nucl Med; 2017 Aug; 58(8):1300-1306. PubMed ID: 28183994 [TBL] [Abstract][Full Text] [Related]
20. Association of CSF Aβ, amyloid PET, and cognition in cognitively unimpaired elderly adults. Guo T; Shaw LM; Trojanowski JQ; Jagust WJ; Landau SM; Neurology; 2020 Oct; 95(15):e2075-e2085. PubMed ID: 32759202 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]